NCPA's qAM

qAM

Consumer level recall: Promacta

by NCPA | May 15, 2019

Novartis has announced a consumer level recall of certain lots of Promacta (eltrombopag) 12.5 mg for oral suspension. Only one strength is affected. Any inventory on pharmacy shelves should be handled as directed by the supplier. Pharmacies should review dispensing records, contact patients who may have received a recalled lot, and provide those patients an avenue to determine further course of action.